Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Jul 17

PMID 32668748

Citations 14

Authors

Paula Sousa

Maria Manuela Estevinho

Claudia Camila Dias

Paula Ministro

Uri Kopylov

Silvio Danese

Laurent Peyrin-Biroulet

Fernando Magro

Affiliations

Soon will be listed here.

Abstract

Many questions remain unanswered regarding therapeutic drug monitoring (TDM) utility with thiopurines. This study aims to establish a relationship between thiopurines' metabolites and drug toxicity. We performed a systematic review with inclusion of studies evaluating the relationship between thiopurines' metabolites and drug toxicity. Meta-analysis of mean difference (MD), correlations and odds ratio (OR) was performed. We identified 21,240 records, 72 of which were eligible for meta-analysis. Levels of 6-thioguanine nucleotides (6-TGN) were higher in patients with leukopenia (MD 127.06 pmol/8 × 10 RBC) and gastrointestinal intolerance (MD 201.46 pmol/8 × 10 RBC), and lower in patients with hepatotoxicity (MD -40.6 pmol × 10 RBC). We established a significant correlation between 6-TGN and leukocytes (r = -0.21), neutrophils (r = -0.24) and alanine aminotransferase levels (r = -0.24). OR for leukopenia in patients with elevated 6-TGN was 4.63 (95%CI 2.24; 9.57). An optimal cut-off of 135 pmol/8 × 10 RBC for leukopenia was calculated (sensitivity 75.4%; specificity 46.4%). 6-methylmercaptopurine ribonucleotides (6-MMPR) were significantly associated with hepatotoxicity (MD 3241.2 pmol/8 × 10 RBC; OR 4.28; 95%CI 3.20; 5.71). Levels of 6-MMPR measured in the first 8 weeks of treatment were associated with leukopenia. We conclude that TDM could be used to prevent thiopurines' toxicity. As optimal metabolites level may vary according to indication, physicians may adapt posology to decrease toxicity without compromising efficacy.

Citing Articles

Dramatic Changes in Thiopurine Metabolite Levels in a Patient With Inflammatory Bowel Disease Treated With Tirzepatide for Weight Loss.

Klein J, St-Pierre J, Choi D, Lopez J, Rubin D ACG Case Rep J. 2024; 11(11):e01544.

PMID: 39507506 PMC: 11540429. DOI: 10.14309/crj.0000000000001544.

Effects of genetic and clinical factors on thiopurine drugs pharmacokinetics in Tunisian patients.

Chadli Z, Hannachi I, Ben Belgacem M, Guediche A, Ben Romdhane H, Kerkeni E Pharmacogenomics. 2024; 25(10-11):441-450.

PMID: 39382000 PMC: 11492722. DOI: 10.1080/14622416.2024.2406739.

Hepatotoxicity in inflammatory bowel disease: Immunomodulators, biologics, and beyond.

Bjornsson H, Bjornsson E Clin Liver Dis (Hoboken). 2024; 23(1):e0199.

PMID: 38881727 PMC: 11177820. DOI: 10.1097/CLD.0000000000000199.

Thiopurine Exposure During Pregnancy is Not Associated With Anemia in Infants Born to Mothers With IBD.

Yeaman F, Stritzke A, Kuret V, Sharifi N, Seow C, Metcalfe A Crohns Colitis 360. 2023; 5(4):otad066.

PMID: 37941596 PMC: 10629965. DOI: 10.1093/crocol/otad066.

Pharmacogenomics of Old and New Immunosuppressive Drugs for Precision Medicine in Kidney Transplantation.

Turolo S, Edefonti A, Syren M, Montini G J Clin Med. 2023; 12(13).

PMID: 37445489 PMC: 10342352. DOI: 10.3390/jcm12134454.

References

Feng R, Guo J, Zhang S, Qiu Y, Chen B, He Y . Low 6-thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease. J Gastroenterol Hepatol. 2018; 34(4):679-685. DOI: 10.1111/jgh.14465. View

Fei X, Shu Q, Zhu H, Hua B, Wang S, Guo L . NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients. Front Pharmacol. 2018; 9:460. PMC: 5949564. DOI: 10.3389/fphar.2018.00460. View

Kopylov U, Amre D, Theoret Y, Deslandres C, Seidman E . Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2014; 59(4):511-5. DOI: 10.1097/MPG.0000000000000455. View

Banerjee S, Bishop W . Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center. J Pediatr Gastroenterol Nutr. 2006; 43(3):324-30. DOI: 10.1097/01.mpg.0000228135.31793.9f. View

Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A . Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2008; 23(9):1373-7. DOI: 10.1111/j.1440-1746.2008.05419.x. View

Gardiner S, Gearry R, Begg E, Zhang M, Barclay M . Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol. 2008; 6(6):654-60. DOI: 10.1016/j.cgh.2008.02.032. View

Bergan S, Rugstad H, Bentdal O, Stokke O . Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes. Transplantation. 1994; 58(7):803-8. View

Shipkova M, Armstrong V, Wieland E, Oellerich M . Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem. 2003; 49(2):260-8. DOI: 10.1373/49.2.260. View

Chrzanowska M, Kolecki P, Fiet J . Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Eur J Pharm Sci. 1999; 8(4):329-34. DOI: 10.1016/s0928-0987(99)00027-5. View

10.

Shaye O, Yadegari M, Abreu M, Poordad F, Simon K, Martin P . Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007; 102(11):2488-94. DOI: 10.1111/j.1572-0241.2007.01515.x. View

11.

Osterman M, Kundu R, Lichtenstein G, Lewis J . Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006; 130(4):1047-53. DOI: 10.1053/j.gastro.2006.01.046. View

12.

Ohtsuka Y, Arai K, Aoyagi Y, Fujii T, Yamakawa Y, Ohtani K . Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease. J Gastroenterol Hepatol. 2010; 25(10):1626-30. DOI: 10.1111/j.1440-1746.2010.06364.x. View

13.

Chrzanowska M, Krzymanski M . Determination of 6-thioguanine and 6-methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine. Ther Drug Monit. 1999; 21(2):231-7. DOI: 10.1097/00007691-199904000-00015. View

14.

Cuffari C, Li D, Mahoney J, Barnes Y, Bayless T . Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy. Dig Dis Sci. 2004; 49(1):133-7. DOI: 10.1023/b:ddas.0000011614.88494.ee. View

15.

Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P . 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006; 12(4):251-7. DOI: 10.1097/01.MIB.0000206544.05661.9f. View

16.

Lancaster D, Lennard L, Rowland K, Vora A, Lilleyman J . Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol. 1998; 102(2):439-43. DOI: 10.1046/j.1365-2141.1998.00812.x. View

17.

Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H . Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006; 55(10):1423-31. PMC: 1856436. DOI: 10.1136/gut.2005.074930. View

18.

Boulieu R, Lenoir A, Bertocchi M, Mornex J . Intracellular thiopurine nucleotides and azathioprine myelotoxicity in organ transplant patients. Br J Clin Pharmacol. 1997; 43(1):116-8. DOI: 10.1111/j.1365-2125.1997.tb00043.x. View

19.

Yarur A, Gondal B, Hirsch A, Christensen B, Cohen R, Rubin D . Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2017; 52(6):537-544. DOI: 10.1097/MCG.0000000000000889. View

20.

Derijks L, Gilissen L, Engels L, Bos L, Bus P, Lohman J . Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004; 26(3):311-8. DOI: 10.1097/00007691-200406000-00016. View